What this study is
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization.
The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.
Study details
- Official title
- Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
- Sponsor
- bioAffinity Technologies Inc.
- Conditions
- Lung Cancer
- Enrolling
- 500 people
- Starts
- 2018-03-01
- Est. completion
- 2025-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Male or female
- 21 years of age or older
- Willing to provide primary care physician contact information to the investigator and agree to have medical information released if indicated
- Meet requirements of one of three cohorts in the study: Healthy Cohort: Current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease. High Risk Cohort: Individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years, or current non-smoker who has a smoking history of at least 30 pack-years, and quit smoking within the past 15 years. Cancer Cohort: Individual who has been diagnosed by a physician as highly suspect for having lung cancer but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
You can't join if
- Severe obstructive lung disease and unable to cough with sufficient exertion to produce a sputum sample. Participants with lung disease that are able to cough with sufficient exertion to produce a sputum sample are not excluded from the study
- Angina with minimal exertion
- Pregnancy
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openAtlantic Respiratory Institute
Summit, New Jersey, United States
- Marissa Rienton-Lim, CCRC · Contact908-934-0440marissa.rienton-lim@atlantichealth.org
- Robert Sussman, MD · Principal investigator
RecruitingRadiology Associates of Albuquerque
Albuquerque, New Mexico, United States
- Timothy P. Zannes, JD · Contact505-506-0853tz@bioaffinitytech.com
- Eugenio Rivera, MD · Principal investigator
RecruitingSouth Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital
San Antonio, Texas, United States
- Jennifer Whitehead · Contact210-834-1344Jennifer.Whitehead@va.gov
- Sheila Habib, MD · Principal investigator
Recruiting
Study team
Sponsor
bioAffinity Technologies Inc.
Study ID BA-002
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.